Literature DB >> 36112226

Dead space management strategies in the treatment of chronic osteomyelitis: a retrospective review.

Gadi Epstein1, Nando Ferreira2.   

Abstract

PURPOSE: Dead space management is critically important during the treatment of chronic osteomyelitis. Many dead space management strategies are available, each with their respective advantages and shortcomings. This study aims to present the outcomes and complications of dead space management strategies employed in the treatment of chronic osteomyelitis at a single tertiary level musculoskeletal unit.
METHODS: A retrospective review of dead space management strategies employed at a tertiary-level musculoskeletal infection unit was conducted. Patients of any age treated for chronic osteomyelitis of the appendicular skeleton with a minimum follow-up of 6 months were included in the study. Data were collected regarding patient demographics, aetiology and site of infection, dead space management strategy employed, follow-up period and outcome in terms of resolution of infection.
RESULTS: A final cohort of 132 patients underwent surgical treatment with a dedicated dead space management strategy for chronic osteomyelitis of the appendicular skeleton. Eleven patients (8%) experienced a recurrence of infection. Seven patients (63%) with recurrence were type B hosts, while four patients (37%) were type A hosts.
CONCLUSION: Dead space management is an integral part of treating chronic osteomyelitis; however, no guidelines currently exist regarding the most appropriate strategy. Favourable results are achievable in low to middle-income countries, and it is evident that no dead space management strategy is superior to another. The pursuit for the ideal void filler is ongoing. LEVEL OF EVIDENCE: III.
© 2022. The Author(s), under exclusive licence to Springer-Verlag France SAS, part of Springer Nature.

Entities:  

Keywords:  Bioactive glass; Cement spacer; Cerament; Chronic osteomyelitis; Dead space management; Lautenbach; Osteoset

Year:  2022        PMID: 36112226     DOI: 10.1007/s00590-022-03392-y

Source DB:  PubMed          Journal:  Eur J Orthop Surg Traumatol        ISSN: 1633-8065


  23 in total

Review 1.  Antibiotic resistance of bacteria in biofilms.

Authors:  P S Stewart; J W Costerton
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

2.  Multicellular resistance: biofilms.

Authors:  P S Stewart
Journal:  Trends Microbiol       Date:  2001-05       Impact factor: 17.079

3.  Surgical treatment of osteomyelitis.

Authors:  George Cierny
Journal:  Plast Reconstr Surg       Date:  2011-01       Impact factor: 4.730

4.  Biomaterial-centered infection: microbial adhesion versus tissue integration.

Authors:  A G Gristina
Journal:  Science       Date:  1987-09-25       Impact factor: 47.728

Review 5.  Biofilms: survival mechanisms of clinically relevant microorganisms.

Authors:  Rodney M Donlan; J William Costerton
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

6.  Chronic osteomyelitis. The effect of the extent of surgical resection on infection-free survival.

Authors:  A H Simpson; M Deakin; J M Latham
Journal:  J Bone Joint Surg Br       Date:  2001-04

Review 7.  Diagnosis and treatment of infections associated with fracture-fixation devices.

Authors:  Andrej Trampuz; Werner Zimmerli
Journal:  Injury       Date:  2006-05       Impact factor: 2.586

8.  Radiographic and Histological Analysis of a Synthetic Bone Graft Substitute Eluting Gentamicin in the Treatment of Chronic Osteomyelitis.

Authors:  Jamie Ferguson; Nicholas Athanasou; Michael Diefenbeck; Martin McNally
Journal:  J Bone Jt Infect       Date:  2019-03-16

9.  A systematic review of the single-stage treatment of chronic osteomyelitis.

Authors:  Bethan Pincher; Carl Fenton; Rathan Jeyapalan; Gavin Barlow; Hemant K Sharma
Journal:  J Orthop Surg Res       Date:  2019-11-28       Impact factor: 2.359

Review 10.  Biofilms: microbial life on surfaces.

Authors:  Rodney M Donlan
Journal:  Emerg Infect Dis       Date:  2002-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.